CHRISTIAN HANSEN Chr. Hansen Q3 2021/22
Investor presentation July 7, 2022
Safe harbor statement
This presentation contains forward-looking statements that reflect management's current views and expectations with respect to Chr. Hansen's future and potential financial performance.
Those forward-looking statements are based upon data and information currently available to the company, and on a variety of assumptions, many of which may be beyond our control and subject to risks and uncertainties that may cause the actual results of the Company or the industry to differ materially from such forward-looking statements.
The information, opinions and forward-looking statements contained in this document speak only as at the date of it and the company is under no obligation to publish any updates thereof except for what is required by applicable law or stock exchange rules and regulations.
Solid results in an uncertain macroeconomic environment
Financial highlights Q3/YTD 2021/22
ORGANIC GROWTH | EBIT MARGIN | FREE CASH FLOW |
before special items | before acquisitions and special items | |
9% | 26.7% (-2.6% vs. LY) | EUR 30m |
YTD 2021/22: 11% | YTD 2021/22: 26.3% | YTD 2021/22: EUR 116m |
(-1.0% vs. LY) | ||
3
Focus on commercial execution, supply security and inflation-driven pricing
Strategic and operational highlights Q3/YTD 2021/22
2025 STRATEGY | ORGANIC GROWTH | |||
Q3/YTD 2021/22 | ||||
29% | ||||
REINVEST | REINVEST | 25% | ||
Strong demand for productivity | Human Health's combined strain- | |||
and yield-optimizing solutions in | to-solution offering presented at | |||
FC&E | several industry events | |||
11% | ||||
9% | 9% | |||
7% | ||||
LEVERAGE | GROUP | |||
New products for meat alternatives, | ||||
Inflation-drivenpricing measures | ||||
cream cheese and beer launched in | ||||
started to contribute positively | ||||
Fermented Plant Bases | ||||
Core1 | Lighthouses1 | Group | ||
Q3 21/22 | YTD 21/22 |
1 Core includes FC&E ex. Bioprotection and Fermented Plant Bases, Human Health and Animal Health. Lighthouses includes Bioprotection, Fermented Plant Bases, HMO and Plant Health.
4
Solid growth in FC&E and strong growth in H&N
Sales performance by segment
Organic growth by business | ||
GROUP1 | FOOD CULTURES & ENZYMES | HEALTH & NUTRITION2 |
9% | 13% | ||||||||||||||||||||||||||||||||||||||
6% | |||||||||||||||||||||||||||||||||||||||
9% | 9% | 10% | 10% | 4% | 6% | 9% | 14% | 8% | 5% | 8% | 8% | 5% | 10% | 7% | 7% | 12% | 18% | 15% | 14% | 0% | 13% | 26% | |||||||||||||||||
-4% | |||||||||||||||||||||||||||||||||||||||
Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | |||||||||||||
19/20 | 20/21 | 21/22 | 19/20 | 20/21 | 21/22 | 19/20 | 20/21 | 21/22 | |||||||||||||||||||||||||||||||
VOLUME/ | PRICE | FX | EUR | VOLUME/ | PRICE | FX | EUR | VOLUME/ | PRICE | FX | EUR | ||||||||||||||||||||||||||||
MIX | GROWTH | MIX | GROWTH | MIX | GROWTH | ||||||||||||||||||||||||||||||||||
Q3 | +7% | +2% | +4% | +13% | Q3 | +4% | +2% | +3% | +9% | Q3 | +12% | +1% | +8% | +21% | |||||||||||||||||||||||||
YTD | +9% | +2% | +3% | +14% | YTD | +6% | +1% | +1% | +8% | YTD | +17% | 0% | +6% | +23% | |||||||||||||||||||||||||
1 Historic figures refer to continuing operations (i.e., excluding Natural Colors).
2 The acquisition of HSO HC is included in organic growth since Q3 2020/21 (closing April 2020), UAS Labs (closing July 2020) and Jennewein (closing October 2021) since Q1 2021/22.
5
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Chr. Hansen Holding A/S published this content on 06 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 July 2022 07:13:01 UTC.
